{
    "clinical_study": {
        "@rank": "148128", 
        "arm_group": [
            {
                "arm_group_label": "Moderate renal impairment group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group"
            }, 
            {
                "arm_group_label": "Severe renal impairment group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group"
            }, 
            {
                "arm_group_label": "Matching healthy control group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with normal renal function defined as eGFR \u2265 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight  can be enrolled in this group."
            }
        ], 
        "brief_summary": {
            "textblock": "To characterize the pharmacokinetics and safety of buparlisib following a single 50 mg oral\n      dose in subjects with moderate and severe renal impairment."
        }, 
        "brief_title": "Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Impairment", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Other than renal impairment, subjects should be in good health as determined by past\n             medical history, physical examination, vital signs, electrocardiogram, (except for\n             additional inclusion criteria for renal impaired patients).\n\n          -  Subjects must have a BMI between 18 kg/m2 and 34 kg/m2 and weight at least 50 kg and\n             no more than 120 kg.\n\n               -  Additional criteria for renal impaired subjects: - Subjects must have stable\n                  renal disease without evidence of renal progressive disease defined as moderate\n                  renal impairment (eGFR 30-59 mL/min/1.73m2) or severe renal impairment (eGFR\n                  15-29 mL/min/1.73m2).\n\n               -  Additional criteria for matched healthy control subjects: - Matched to at least\n                  one renal impaired subject by gender, race, age (\u00b1 10 years), and weight (\u00b1\n                  20%).\n\n          -  An estimated GFR as determined by MDRD equation within normal range as determined by\n             eGFR \u2265 90 mL/min/1.73m2\n\n        Exclusion Criteria:\n\n          -  Significant illness, including infections, or hospitalization within the 2 weeks\n             prior to dosing, except for the renal impaired subjects who due to their renal\n             disease may be affected by significant medical problems which require frequent\n             hospitalizations.\n\n          -  Any surgical or medical condition that may significantly alter the absorption,\n             distribution, metabolism, or excretion of drugs, or which may jeopardize the subject\n             in case of participation in the study\n\n          -  Subject has a medical history of cardiac disease and/or clinically significant ECG\n             abnormalities within 6 months prior to screening.\n\n          -  Subject has an active or a history within 6 months prior to screening of clinically\n             significant hematologic, endocrinologic, pulmonary, cardiovascular, hepatic, or\n             allergic disease, medically documented (other than clinical conditions associated\n             with renal impairment for the renal impaired subjects only).\n\n          -  - Additional exclusion criteria for renal impaired subjects: - Severe albuminuria >\n             300 mg/day.\n\n          -  Subjects undergoing any method of dialysis.\n\n          -  Subjects with renal impairment due to hepatic disease (hepatorenal syndrome).\n\n          -  Subjects with clinically significant abnormal findings, not consistent with clinical\n             disease, upon physical examination, ECG or laboratory evaluation.\n\n          -  Use of any prescription or non-prescription medication that has the potential to\n             interact with buparlisib within two weeks prior to dosing or during the study.\n\n          -  - Additional criteria for matched healthy control subjects: - Use of any prescription\n             or non-prescription medication or vitamins during 14 days prior to dosing.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048787", 
            "org_study_id": "CBKM120C2113", 
            "secondary_id": "2013-003384-64"
        }, 
        "intervention": {
            "arm_group_label": [
                "Moderate renal impairment group", 
                "Severe renal impairment group", 
                "Matching healthy control group"
            ], 
            "description": "Subjects will receive a single dose of 50 mg buparlisib.", 
            "intervention_name": "Buparlisib", 
            "intervention_type": "Drug", 
            "other_name": "BKM120"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Renal impairment", 
            "Healthy volunteers", 
            "Clinical pharmacology study"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1612"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 4", 
                        "country": "Czech Republic", 
                        "zip": "140 59"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucuresti", 
                        "country": "Romania"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Troitsk", 
                        "country": "Russian Federation", 
                        "state": "Russia", 
                        "zip": "142190"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Czech Republic", 
                "Germany", 
                "Romania", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Single Dose, Multicenter Study to Evaluate the Pharmacokinetics and Safety of 50 mg Oral Buparlisib in Subjects With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Volunteers.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Paul-Ehrlich-Institut", 
                "Czech Republic: State Institute for Drug Control", 
                "Romania: National Medicines Agency", 
                "Bulgaria: Bulgarian Drug Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the maximum plasma concentration (PK parameter Cmax). Cmax directly determined from the plasma concentration-time profiles.", 
                "measure": "Plasma pharmacokinetic (PK) parameter Cmax", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter AUCinf (area under the plasma concentration-time curve from time 0 to infinity). AUC determined from the plasma concentration-time profile using non-compartmental analysis.", 
                "measure": "Plasma PK parameter AUCinf", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter AU0-t (area under the plasma-concentration time curve from timepoint 0 to time t). AUC determined from the plasma concentration-time profile using non-compartmental analysis.", 
                "measure": "Plasma PK parameter AUC0-t", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter CL/F (clearance).", 
                "measure": "Plasma PK parameter CL/F", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the urine clearance CLR.", 
                "measure": "Urine PK parameter CLR", 
                "safety_issue": "No", 
                "time_frame": "predose, 0-4 h, 4-8 h, 8-12 h, 12-24 h, 24-48 h, 48-72 h, 72-96 h, 96-120 h, 120-144 h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048787"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Tmax (time to reach maximum plasma concentration), directly determined from the plasma concentration-time profile.", 
                "measure": "Plasma PK parameter Tmax", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter T1/2 (terminal half-life).", 
                "measure": "Plasma PK parameter T1/2", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Vz/F (the apparent volume of distribution following extravascular administration).", 
                "measure": "Plasma PK parameter Vz/F", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on plasma protein binding. Fraction of buparlisib unbound will be determined (Fu).", 
                "measure": "Plasma Protein Binding", 
                "safety_issue": "No", 
                "time_frame": "predose, 1 hour post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Cmax,u (Cmax,u is the observed maximum unbound plasma concentration following administration).", 
                "measure": "Unbound plasma PK parameter Cmax,u", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameters AUCinf,u (AUCinf,u is the area under the unbound plasma concentration-time curve extrapolated to infinity).", 
                "measure": "Unbound plasma PK parameter AUCinf,u", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter Vu/F (the apparent unbound drug volume of distribution following extravascular administration).", 
                "measure": "Unbound plasma PK parameter Vu/F", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameter CLu/F (the unbound systemic clearance from plasma).", 
                "measure": "Unbound plasma PK parameter CLu/F", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the urine PK parameter Ae0-t (the amount of unchanged buparlisib excreted into the urine from time 0 to a defined point in time).", 
                "measure": "Urine PK parameter Ae0-t", 
                "safety_issue": "No", 
                "time_frame": "predose, 0-4 h, 4-8 h, 8-12 h, 12-24 h, 24-48 h, 48-72 h, 72-96 h, 96-120 h, 120-144 h"
            }, 
            {
                "description": "Determination of the relationship between the primary PK parameters (Cmax, AUCinf, AUC0-t, CL/F and urine PK parameter CLR) and renal function parameters eGFR (estimated glomerular filtration rate using the equation from the Modification of Diet in Renal Disease (MDRD) study) and CLCr estimated using Cockcroft-Gault equation.", 
                "measure": "Relationship between PK parameters Cmax, AUCinf, AUC0-t, CL/F, urine CLR and renal function.", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }, 
            {
                "description": "Assessment of safety and tolerability of a single dose buparlisib in renal impaired subjects compared with healthy control subjects by assessing the frequency and severity of Adverse Events based on the CTCAE criteria.", 
                "measure": "Adverse Events severity and frequency", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline Day 1 to 30 days post-dose"
            }, 
            {
                "description": "Assessment of safety and tolerability of a single dose buparlisib in renal impaired subjects compared with healthy control subjects by assessing the change from baseline in hematological and biochemical laboratory parameters.", 
                "measure": "Change from baseline in laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline Day 1 to 30 days post-dose"
            }, 
            {
                "description": "Assessment of safety and tolerability of a single dose buparlisib in renal impaired subjects compared with healthy control subjects by assessing the change from baseline in ECG parameters.", 
                "measure": "Change from baseline in ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline Day 1 to 30 days post-dose"
            }, 
            {
                "description": "Measurement of effect of renal impairment on PK of buparlisib by assessment of the PK parameters AUC0-t,u (AUC0-t,u is the area under the unbound plasma concentration-time curve from time zero to time t).", 
                "measure": "Unbound plasma PK parameter AUC0-t,u", 
                "safety_issue": "No", 
                "time_frame": "predose, 10, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240 hours post-dose"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}